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INTRODUCTION
Clozapine is a dibenzodiazepine derivative which has recep-
tor blocking activity at dopamine D1 and D4 as well as seroto-
nin 5-HT1A and 5-HT2 receptors.
1,2 It is an atypical antipsycho-
tic that has been shown to be effective in treating patients with 
refractory schizophrenia.
3 Clozapine also is less likely to cause 
extrapyramidal adverse effects including tardive dyskinesia 
than other antipsychotics.
4 However, it has propensity to cause 
severe adverse effects such as agranulocytosis (1-2%)
5 and an 
unusually high incidence of seizures.
6,7 
Recent estimates of incidence of clozapine-induced seizures 
vary from 1.3%
8 to 2.8%.
9 Even higher occurrence rates of sei-
zures have been reported in more selected populations such 
as state hospital patients
10 or brain injured patients.
11 There is 
evidence that the risk for seizures is dose-related,
7,12 although sei-
zures can occur in all dose ranges
10 and even at very low doses.
13 
Electroencephalogram (EEG) abnormalities have been re-
ported to occur frequently in several retrospective studies of pa-
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tients treated with clozapine;
14-18 it ranges from 53%
17 and 59%
15 
to 74%.
18 Generalized slowing has been reported as the most 
prominent finding, followed by epileptiform activities such as 
spike-waves and sharp activities.
15,17-19 Several but not all stud-
ies found EEG changes associated with clozapine to be dose-
related.
17,18,20 Furthermore, studies have shown that the plasma 
levels of clozapine predict pathological EEG changes as well as 
the occurrence of seizures.
21,22 Some of these seemingly contra-
dictory observations might be explained by clozapine’s wide 
range of plasma level for a given dose.
21 Volavka et al.
23 report-
ed that clozapine differed from the other antipsychotics by pro-
ducing more EEG slowing and epileptiform activity. The aim 
of our study was to explore and characterize the EEG abnor-
malities associated with clozapine treatment. 
METHODS
This was a cross-sectional study conducted at Center for Cog-
nitive Neurosciences, Central Institute of Psychiatry, Ranchi, 
India. Sample consisted of 87 patients on clozapine treatment 
for various psychiatric disorders. All the patients were receiv-
ing clozapine for at least two weeks. Patients with history of sei-
zures in the recent past were excluded from the study. Digital 
EEG was recorded in awake state with eyes closed using 21 Ag-
AgCl electrodes (32 channels) placed according to the inter-
national 10-20 system using Neurofax EEG-9000 (Nihon Ko-
hden, Japan) amplifiers (sampling rate 512 Hz, TC 0.1 Sec., 
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HFF 70 Hz) with linked ear electrodes as reference. Three mi-
nutes of hyperventilation as well as photic stimulation in dif-
ferent frequencies were also obtained. Visual analysis of the 
EEG was carried out by the author NG, having experience in 
EEG interpretation after appropriate training, to characterize 
background activity as well as to identify slow waves and epi-
leptiform activity (spike-waves, polyspike-waves or sharp wa-
ves) and their localization. EEG abnormalities were categoriz-
ed on the basis of duration of abnormalities in 95 to 100 epochs 
each of 10 seconds duration in real time that were characteriz-
ed as ‘mild’ (<25% of epochs), ‘moderate’ (25-50% of epochs), 
and ‘severe’ (>50% of epochs or polyspikes). 
The data obtained were analyzed with Statistical Package for 
Social Sciences-version 10.0 for Windows
® (SPSS Inc., Chica-
go, IL, USA). Continuous variables were analyzed using inde-
pendent sample ‘t’ test and categorical data was analyzed us-
ing Pearson’s chi-square test. Level of significance was set at p< 
0.05 (two-tailed). Logistic regression analysis (backward con-
ditional method) was carried out with presence or absence of 
EEG abnormality as outcome variable. Age, gender, clozapine 
dose, duration on clozapine and medications were entered as 
predictor variables. 
RESULTS
Sample consisted of 76 (87.4%) males and 11 (12.6%) fema-
les. Mean age of the sample was 32.76 (SD 11.10) years and 
mean duration of illness was 92.39 (SD 64.79) months. Entire 
sample was right handed. Daily clozapine doses varied from 
25 to 800 (mean 293.10, SD 172.55) mg/day and mean dura-
tion on clozapine was 15.07 (SD 8.98) weeks. Fifty-six (64.4%) 
patients were on clozapine alone, whereas 19 (21.8%) received 
valproate, 7 (8%) other antipsychotics and 5 (5.7%) antide-
pressants along with clozapine. Sixty-three (72.4%) had schi-
zophrenia, 9 (10.3%) had mood disorders and 6 (6.9%) had 
schizoaffective disorder. Five (5.7%) patients had past history 
of epilepsy during childhood and three (3.4%) patients had 
head injury or central nervous system infection. EEG abnor-
malities associated with clozapine are summarized in Table 1. 
There was no difference in clozapine dose between patients 
with or without EEG abnormalities (t=0.96, p=0.342). Ab-
normal EEG was found in 34 (66.7%) patients receiving cloza-
pine more than 300 mg/day, whereas it was seen in 21 (58.3%) 
patients receiving clozapine less than 300 mg/day. Among those 
receiving clozapine 100 mg or less per day (n=21), EEG was 
abnormal in 13 (61.9%) patients, whereas in those receiving 
clozapine 50 mg or less per day (n=12) and 25 mg or less per 
day (n=7), abnormal EEG was found in 6 (50%) and 4 (57.1%) 
patients, respectively. Abnormal EEG was found in 38 (67.9%), 
11 (57.9%), 3 (42.9%) and 3 (60%) patients, among those re-
ceiving clozapine only, clozapine with sodium valproate, clo-
zapine with antipsychotics and clozapine with antidepres-
sants, respectively. 
There was no difference in the frequency of EEG abnorma-
lities (χ2=1.45, p=0.228), presence of slow waves (χ2=0.14, p= 
0.707) or epileptiform activities (χ2=0.69, p=0.406) among 
patients receiving clozapine alone or clozapine with other 
drugs. There was no significant difference in age, sex, duration 
of illness and duration on clozapine treatment between the 
patients with or without EEG abnormalities (Table 2). Thirty-
eight (69.1%) patients out of 63 patients with schizophrenia 
had abnormal EEG, although it was not significantly higher 
than patients with other diagnoses (χ2=0.83, p=0.36). None of 
the patients developed clinical seizures. Logistic regression an-
alysis did not identify any significant predictors of EEG abnor-
malities (Table 3).
Table 1. Frequency of EEG abnormalities associated with clozap-
ine (N=87)
EEG abnormalities N %
Abnormal EEG 55 63.2
Background asymmetry 1 1.1
Background asynchrony 0 0
Poorly regulated background 1 1.1
Slow waves present 36 41.4
Slow wave details
Focal 8 9.2
Regional 7 8.0
Lateralized 1 1.1
Generalized 17 19.5
Combination 3 34
Slow wave type
Theta 18 20.7
Delta 8 9.2
Both 9 10.3
Epileptiform activity 36 41.4
Epileptiform activity details
Focal 6 6.9
Regional 8 9.2
Lateralized 1 1.1
Generalized 13 14.9
Combination 7 8.0
Abnormality with activation procedures 4 4.6
Severity of abnormality
Mild 5 5.7
Moderate 26 29.9
Severe 24 27.6
EEG: electroencephalogram374  Psychiatry Investig 2011;8:372-376
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DISCUSSION
The overall frequency of EEG abnormality was high (63.2%) 
in our study, that is consistent with the existing literature. EEG 
abnormalities occurred in 66.7% of patients receiving more 
than clozapine 300 mg/day; similar rates (72%) were reported 
earlier.
14 Treves and Neufeld
24 had found EEG abnormalities 
in 64% of patients under clozapine at 300 mg/day. Slowing of 
EEG in theta and delta range has been more frequent as com-
pared to epileptiform activities in most studies,
19 whereas, in 
our study both were equally prevalent (-40%).
In their retrospective review, Gunther et al.
17 found a dose 
dependent relationship between clozapine dose and EEG sl-
owing, with 92% of 283 patients receiving more than 600 mg 
clozapine exhibiting diffuse slowing. Liukkonen et al.
25 report-
ed background disturbance in 11, paroxysmal slow wave ac-
tivity in 8, and epileptiform discharges in 4 out of 12 patients; 
patients with epileptiform discharges were on clozapine 300-
700 mg daily. In our study no such association was found. Ne-
vertheless, moderate to severe abnormalities were more fre-
quent in our study. Interestingly, EEG abnormalities were pre-
sent in more than 50% patients, even in those receiving lower 
doses of clozapine (less than 100, 50 or 25 mg per day). This 
finding underscores the importance of EEG monitoring in 
patients on lower doses of clozapine. However, these EEG ab-
normalities are not specific and the epileptiform activity is not 
necessarily associated with seizures, as observed in our study. 
Quantitative EEG studies have reported an increase in theta 
and delta power and coherence changes in theta band fol-
lowing clozapine treatment.
26 In that study, changes of coher-
ence were correlated with changes on the Brief Psychiatric Rat-
ing Scale score, thus to clinical improvement. In a case study, 
sharp-slow wave activity was found bilaterally over frontal 
regions, and further source analysis localized these to the deep 
medial frontal region.
27 Further studies are required to char-
acterize these EEG changes prospectively.
The mechanism of clozapine-induced seizure is not known, 
although its effect on gamma-aminobutyric acid A (GABAA) 
receptors
28 has been implicated. The other possible mecha-
nisms include its action on nicotinic acetylcholine receptors,
29 
glutamate N-methyl-D-aspartate (NMDA) receptors,
30 sero-
tonin 5-HT2A
31 and strychnine-sensitive glycine receptors33 
that merits further evaluation. In a mouse model, expression 
of immediate early gene such as c-fos has been found in num-
Table 2. Comparison of clinical characteristics between those with and without EEG abnormalities associated with clozapine
Without EEG abnormalities
(N=32)
With EEG abnormalities
(N=55) t/χ2 p
Age, Mean (SD) 35.16 (9.87)00 31.37 (11.62)0 1.55 0.13
Duration of illness (mths), Mean (SD) 96.59 (59.96)0 89.94 (67.87)0 0.46 0.65
Duration on clozapine (wks), Mean (SD) 14.31 (9.20)00 15.52 (8.91)00 -0.60 0.55
Clozapine dose, Mean (SD) 269.92 (170.06) 306.59 (174.10) -0.96 0.34
Gender, n (%) Male 30 (93.8)00 46 (83.6)00 1.87 0.17
Female 2 (6.2)000 9 (16.4)00
Diagnosis, n (%) Schizophrenia 25 (78.1)00 38 (69.1)00 0.83 0.36
Other diagnosis 7 (21.9)00 17 (30.9)00
Family psychiatric illness, n (%) Present 6 (18.8)00 13 (23.6)00 0.28 0.59
Absent 26 (81.2)00 42 (76.4)00
*p<0.05. EEG: electroencephalogram, SD: standard deviation, mths: months, wks: weeks
Table 3. Logistic regression analysis showing predictors of EEG abnormalities associated with clozapine
Predictors† Wald p Odds ratio
95% confidence interval
Lower Upper
Constant 3.56 0.059 8.09
Age 2.48 0.115 0.97 0.93 1.01
Gender (Male vs. Female) 1.66 0.198 0.34 0.06 1.77
Clozapine dose 0.68 0.408 1.00 0.99 1.01
Duration on clozapine 0.05 0.818 0.99 0.89 1.09
Medication status (clozapine only vs clozapine 
  with other medications)
0.51 0.672 1.24 0.46 3.37
*p<0.05, †predictors from step 1 of backward conditional method. EEG: electroencephalogramN Goyal et al. 
   www.psychiatryinvestigation.org  375
ber of subcortical sites and in orbital cortex of clozapine kindl-
ed myoclonic jerks.
33
Recently it has been suggested that EEG findings should 
not be excessively relied upon as there is no consensus on us-
ing EEG data as a guide for optimal dosing of clozapine.
34 Se-
veral studies
35,36 including ours, show that EEG abnormalities 
may be present without any association with clinical seizures, 
in contrast to the study by Welch et al.
18 which suggested that 
the EEG is a sensitive indicator of clozapine toxicity and that 
changes such as the development of spikes and sharp waves in-
dicate a high risk of convulsions. Larger studies are required 
to clarify this issue further.
In our cohort of 87 patients, EEG changes during clozapine 
therapy were common. Epileptiform activity was found in 
more than 40% of the patients and was of moderate to severe 
degree. However, in absence of baseline EEG, the issue of new 
onset abnormalities could not be clarified. Other limitation 
in our study includes heterogeneity of psychiatric diagnosis, 
the effect of which could not be examined due to small sam-
ple size. Also, serum clozapine levels were not measured in 
our study. It has been found that there are significant inter- 
and intra-individual variations in clozapine serum levels, for 
a given dose, and it has been attributed to its complex meta-
bolism.
21,37 A recent review
38 found that although there was 
evidence for strong relationship between clozapine dose and 
plasma level and occurrence of clozapine-induced EEG ab-
normalities, there was no statistically significant relationship 
between dose and occurrence of seizures. The authors con-
cluded that there is insufficient data to suggest direct relation-
ship of clozapine plasma level with occurrence of seizures, 
though they found three case reports suggesting very substan-
tial risk of seizures with clozapine plasma levels exceeding 
1,300 µg/L.
38 Nevertheless, therapeutic drug monitoring of 
clozapine has been suggested to be useful to identify signs of 
toxicity and onset of seizures.
37 
It is also interesting to note that in Asian patients, the plasma 
clozapine levels were higher with a given dose of clozapine, 
compared to Caucasian patients, and the findings remained 
significant even after controlling for gender, body mass index, 
cigarette, alcohol and caffeine use.
39 Although ethnic differ-
ences in EEG abnormalities and seizures associated with clo-
zapine has not been adequately studied, such variations might 
account for the differences in rates of EEG abnormalities. Two 
case studies
40,41 described seizures occurring at lower clozapine 
doses in Asian patients, with very high serum levels in one re-
port. In our study, frequent EEG abnormalities in those re-
ceiving lower doses of clozapine could reflect such ethnic vari-
ation, though such association is presumptive at best in the ab-
sence of plasma levels. 
EEG abnormalities have also been reported to occur with ty-
pical as well as other atypical antipsychotics. One study
42 com-
pared EEG abnormalities in those receiving antipsychotics 
(n=81) with normal healthy controls (n=30). Abnormal EEG 
was higher in those receiving olanzapine (35%) and haloper-
idol (23%) and was statistically significantly increased with 
dose in the olanzapine group, in contrast to patients treated 
with haloperidol, quetiapine or healthy subjects. Also, epilep-
tiform activity was observed only in patients receiving olanza-
pine (11%). In another study43 on a larger sample (n=323), 
EEG abnormalities were most frequent with clozapine (47%), 
followed by olanzapine (38%), risperidone (28%), typical an-
tipsychotics (14%) and none with quetiapine. In that study, co-
morbid disorders and older age were associated with higher 
risk, whereas there was no relationship with dose or clinical re-
sponse.
There is some evidence to suggest a favorable clinical resp-
onse in specific groups of patients (females, major depressive 
disorder) predicted by EEG abnormalities before clozapine 
treatment.
44 In another study,
45 pretreatment intrahemispheric 
asymmetry on EEG predicted short-term response to cloza-
pine treatment in schizophrenia. Also, EEG abnormalities de-
veloping after clozapine treatment appeared to be associated 
with good response in another small study.
46 
There is no consensus regarding antiepileptic prophylaxis in 
patients on clozapine without clinical seizures; some reports
38 
advising use of these medications at a certain clozapine dose 
or plasma level (>500 µg/L) or appearance of clear epilepti-
form discharges on EEG. However, as shown in our report, 
seizures were absent in patients receiving higher clozapine 
doses, even in the presence of epileptiform discharges on EEG. 
Therefore, routine use of anticonvulsants may not be warrant-
ed in patients having EEG abnormalities, even in those having 
epileptiform discharges. Nevertheless, it appears prudent to 
monitor for the clinical appearance of seizures in these patients, 
specifically with higher doses.
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